New insights into diabetic blindness

New insights into diabetic blindness
Retinal vasculature of an adult transgenic (Fli1:EGFP) zebrafish. After 30 days of hyperglycaemia, these vessels display many of the abnormal features observed in the retinal capillaries of diabetic patients.
( -- New research by University College Dublin scientists indicates that treatment of diabetic blindness should look at protecting the neurons responsible for colour vision in the eye and not just targeting the blood vessels as is currently the practice.

The research team led by Conway Fellow, Dr Breandán Kennedy from the School of Biomolecular & Biomedical Science recently published their findings in the journal Disease Models & Mechanisms.

Nearly 2.5 million people worldwide are blind due to a secondary complication of diabetes called diabetic retinopathy. This disorder activates the growth of new leaky in the eye and is responsible for the death of photoreceptors, the neurons that send visual messages to our brain.

Until now, scientists were unclear if the changes to vessels and neurons occurred independently of one other. Questions were also asked about which type of retinal neuron is most likely to die as a result of the raised glucose levels seen in diabetes.

Dr Kennedy and his team found that new blood vessels and the neuronal cell death in diabetic retinopathy can arise independently of each other. In addition, they identified that cone photoreceptor neurons, those involved in and which we use to see during daylight are most affected by the high glucose levels.

The research team made their observations by successfully generating a zebrafish model of diabetes. The eyes of these small, tropical freshwater fish are very similar in design to humans, making it a useful species to study blindness. The high levels of glucose typically seen in people suffering with diabetes were stimulated in zebrafish and the fish studied to see whether they exhibited known diabetic symptoms.

This novel model of the disease resembles the early stages of diabetic retinopathy in humans. It is an exciting development for the Kennedy group who now hope to further extend their research and establish a model of late stage diabetic disease.

Current treatment for diabetic retinopathy sufferers tries to prevent the growth of new blood vessels in the late stage of the disease. There are associated side effects and the treatments halt but do not cure the disease. This research suggests a need to also protect the neurons before the disease progresses to the late stage.

Commenting on the research, Dr Kennedy said, “By establishing a robust model for early and late stage diabetic retinopathy, we would hope to better understand the progression of the disease and pave the way for identifying new drug targets for its successful treatment”. Provided by University College Dublin

Citation: New insights into diabetic blindness (2010, April 9) retrieved 22 January 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Apr 11, 2010
One might wonder exactly WHAT these researchers ARE studying when they MISS all the iron in the eye. It is well known iron in the eye destroys it. It is also well known there is MORE iron in the eye of a diabetic than is KNOWN to harm the eye but yet they FAIL to target this iron. How can someone KNOW something will destroy something and THEN fail to react TO that substance ? Stupidity is the only answer.

RESULTS: The level of vitreous iron
increased threefold in Eales' disease (1.85 +/- 0.36 pg/ml), 2.5-fold in
proliferative diabetic retinopathy (1.534 +/- 0.17 pg/ml) and 2.3-fold in eyes
with intraocular foreign body (1.341 +/- 0.25 pg/ml) when compared with macular
hole (0.588 +/- 0.16 pg/ml).

This suggests
that the least amount of ferrous ions necessary to cause liquefaction
of the rabbit vitreous is in the range of 16.8 to 39.2 micrograms of
elemental iron, a concentration of 0.3 to 0.7 mM in the vitreous.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more